ESMO® 2025 Highlights: Presenter Vignette – Christof Vulsteke

ESMO® 2025 Highlights: Presenter Vignettes

Christof Vulsteke

MD, PhD

Integrated Cancer Centre Ghent

LBA2

Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study

© All rights reserved

Made with ❤ by Elementor

Oncology Career Hub
Post A Job
Scientific Steering Committee
Events
Podcast

About Us
Contact Us
Terms of Use
Disclaimer
MDBriefCase
RxBriefCase

199 Bay Street #4000
Toronto, ON M5L 1A9

Twitter Instagram Facebook-f Linkedin-in

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Tumour Sites
- Breast
- Colorectal
- GI
- GU
- Gynecology
- Hematology
- Lung
- Melanoma
- Sarcoma
- Other Topics
Events
Oncology Career Hub
- View Openings
- Post A Job
About Us

Search for:

Pre-Video Survey

By continuing to watch the video, you consent to receiving a post-view survey by email.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. See our privacy policy and cookie policy.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies Enabled Disabled

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies Enabled Disabled